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bypass surgery (CABG) were randomized into either a training (T) or an inactive control 
(C) group. At study begin (B) and after 4 weeks (4 wks) average peak velocity in 
response to different dosages of acatylcholine (Ach) was measured invasively using 
Doppler velocimetry, vessel diameter of the LIMA was determined by quantitative angiog- 
raphy. LIMA rings not used for bypass grafting during CABG were removed and sus- 
pended in an organ chamber to determine endothelial function in vitro. Additionally, 
expression of the subunit gp91phox of the NAD(P)H oxidase was measured in samples 
of the LIMA by real time PCR and expressed as ratio over van Willebrand factor. 
ET was associated with a clear increase in APV at the highest dosage of Ach (7.2 rag/ 
min) from 47±5% to 91±10% (p<0.05 vs. C). In vitro the concentration of Ach which was 
necessary to induce 50% relaxation lED50) of the preconstricted LIMA rings was signifi- 
cantly lower in T as compared to C (7.49±0.10 [-log mol/L Ach] vs. 6.82±0.10 [-log mol/L 
Ach}, p<0.05). A considerable reduction of the NAD(P)H oxidase subunit gp91phox 
mRNA expression was observed in T as compared to C (0.47±0.15 vs 1,93±0.60 
arb.units; p<0.05). 
Conclusions: In patients with CAD regular exercise training is associated with an 
enhanced endothelial function in vivo and in vitro. The improvement of endothelial func- 
tion due to ET is paralleled by an attenuated mRNA expression of the subunit gp91phox 
of the NAD(P)H oxidase. These results imply that ET exerts its beneficial effects on the 
endothelial level at least partially by an attenuation of local oxidative stress. 
1080-86 Does Folic Acid Supplementation Improve Endothel ia l  
Function in Coronary Patients Independent of 
Homocysteine Lowering? 
Kam S. Woo, Ping Chook, Qiao Mu, Anna Chan, Wilson Chan, John E. Sanderson, 
David S. Celermajer, The Chinese University of Hong Kong, Hong Kong, Hong Kong. 
Hyperhomocysteinemia is an emerging risk factor for arterial endothelial dysfunction in 
coronary patients (CAD), which can be improved with folic acid supplementation (FA). To 
evaluate whether FA could improve endothelial function independent of homocysteine- 
lowering, 37 CAD with high homocysteine (total fasting homocysteine >12~moVI)(HHC) 
and 39 CAD with normal homocysteine (Normal HC) were studied. FA (5rag/day) or pla- 
cebo were given for 8 weeks to both groups in double blind cross over fashion, with 10 
weeks placebo-washout before crossing over, Flow-mediated dilation (endotheUum- 
dependent, FMD) were measured by high resolution ultrasound before and after each 
treatment period. The 2 groups were matched in age, gender, blood pressures, glucose, 
lipid profiles and coronary scores, but blood creatinine was slightly higher in HHC-CAD 
(108.3:~?.5.7 vs 86.1+17.61~mol/I, p<0.0001 ). FA was associated with significant reduction 
in HC and improvement of FMD in both HHC and Normal HC groups. On multivariate 
analysis, changes in folate but not homocysteine or lipid (LDL-C), baseline creatinine nor 
coronary score, were correlated to changes in FMD, (R=0.4; F value=5.5; p<0.001) 
In conclusion, folic acid supplementation has beneficial effect on endothelial function in 
coronary patients, independent of homocysteine-lowedn~. 
HIGH HC-CAD NORMAL HC-CAD 
FA Placebo FA Placebo 
LDL-C(mmol/I) 3.0±1.1 2.9±1.0 2.9±1.0 3.0±1.0 
HC (p.mol/I) 11,8±2.5" 13.6±3.0 8.8±2.1" 9,8±1.8 
Folate (l~mol/I) 83.6±10.9" 27.5±11.8 82.6±8.7* 34.0±14.7 
FMD (%) 6.1 ± 1.3** 5.4±1.8 5.9±1.6"* 4.9±1.0 
Compared with placebo : *P<0.0001 ; **P<0.005 
1080-87 Vascular  React iv i ty  and Carot id  Int imaI-Medle l  
Thickness in Children With Insulin-Dependent Diabetes 
Mellitus 
Taiinder P. Sinah. Harvey Groehn, Andris Kazmers, Wayne State University School of 
Medicine, Detroit, Michigan, Children's Hospital of MI, Detroit, Michigan. 
Background: Endothelial dysfunction is a precursor of clinically detectable atherosclero- 
sis. Diabetes mellitus is an established risk factor for atherosclerosis. Although vascular 
complications of diabetes are not clinically evident in diabetic children, the timing of onset 
of endothelial dysfunction in diabetic children is unknown, 
Objective: The objective of this study was to test the hypothesis that endothetium- depen- 
dent vasodilation is impaired in children with insulin-dependent diabetes mellitus com- 
pared to age-matched controls. 
Methods: We studied 31 diabetic teenagers (age 15.0 ± 2.4 years, duration of diabetes 
6.8 ± 3.9 years) and 29 age-matched healthy children (age 15.4 ± 2.9 years). Using high- 
resolution vascular ultrasound, we compared brachial artery responses to reactive hype- 
remia (endothelium-dependent vasodilation) and to sublingual nitroglycerine (endothe- 
lium-independent vasodilation). We also measured bilateral carotid intimal-medial 
thickness in the two groups of subjects. 
Results: There was no difference in baseline brachial artery diameter or the degree of 
reactive hyperemia between the two groups. Endothelium-depeedent vasodilation was 
significantly lower in diabetic children compared to healthy children (4.9 ± 3.4% vs. 7.9 ± 
5.8%, P = 0.02). There was no difference in endothelium-independent vasodilation (16 ± 
5% vs. 18 ± 8 %, P = NS) or mean carotid intimal-medial thickness between the groups 
(0.33 ± 0.10 vs. 0.32 ± 0.08 ram, P = NS). There was no relationship of brachial reactivity 
to the diabetic control (Hb At C) or the duration of diabetes. 
Conclusions: Endothelial function is impaired in children with diabetes mellitus within the 
first decade of its onset. Strategies to improve endothelial function in these children may 
have a therapeutic role in this high-risk group. 
1080-88 Endothe l ia l  Funct ion ,  Sk in Capi l lary  Density,  and 
Plasma Endothelln Levels in Hypertensive and 
Normotenslve Pat ients  With Ang ina l  Chest  Pain and 
Normal  Coronary  Ar ter iograma 
Tarek F, Antonios. Guilia Russo, Khaled M. Hasan, Sue J. Brown, Donald R, Singer, SL 
George's Hospital Medical School, London, United Kingdom. 
Background: Patients with anginal chest pain and normal coronary artedes (CP-NCA) 
often have abnormal endothelium-dependent vasedilator responses, reduced coronary 
blood flow reserve, and higher levels of plasma endothelin-1. We recently showed that 
skin capillary density is lower in patients with CP-NCA. 
Aims & Methods: The aim of this study was to examine the relationship between capillary 
density (measured by intra-vital microscopy before and after maximisation with venous 
congestion) and flow-mediated dilatation (FMD) measured by brachial artery Doppler 
ultrasound and plasma endothelin levels. We studied 19 patients With CP-NCA [11 were 
hypertensive (age 60yr, sitting BP on treatment 145/82mmHg) and 8 were normotensive 
(age 60yr, BP 128/75mmHg)] and 9 healthy controls (age 59yr, BP 125/78mmHg). 
Results: Mean capillary density was significantly lower in patients with CP-NCA indepen- 
dent of their BP compared to healthy controls, both at baseline [55±5 in hypertensives, 
61±3 in normotensive versus 73±4 in controls, p=0.001 ANOVA], and after maximisetion 
[60±5, 67±3 versus 85±4 respectively, p<0.0001], FMD was higher in controls than in 
normotansive CP-NCA who in turn had higher values than hypertensive CP-NCA (5,561 
versus 4,329 versus 3.646%, p--0.056. Capillary density was markedly lower with higher 
plasma endothelin-1 levels in subjects with CP-NCA (r= - 0.7, p=0.01). 
Conclusions: We confirmed a significant reduction in baseline and maximal skin capillary 
density in patients with CP-NCA independent of blood pressure. Our findings suggest 
that plasma endothelin-1 may be implicated in the pathogenesis of capillary rarefaction in 
this syndrome. 
1080-89 ACE Inh ib i tora  Improve  Endothe l ia l  Funct ion  of  
Coronary Arterioles From Pat ients  With Atherosclerosla 
by Influencing Local Kinin Release 
Chdstiane P. Tiefenbacher. Stefanie Fdeddch, "Fine Bleeke, University of Heidelberg, 
Heidelberg, Germany. 
ACE-inhibitors attenuate endothelial dysfunction by increasing the availability of NO in 
human coronary arterioles from patients with atherosclerosis. The release of NO by the 
coronary circulation is, in part, regulated by local kinin production in resistance vessels. 
We, therefore, hypothesized that the effect of ACE inhibitors on endothelial dysfunction is 
mediated via influencing local kinin metabolism. 
Methods: In isolated perfused coronary arterioles (<801~M; videomicroscopy) from atrial 
appendage of patients with and without (control) atherosclerosis, dose-responses to the 
endotheliurn-dependent agonists histamine (His), serotonin (5-HT) and acetylcholine 
(ACh) as well as to the endothelium-independent vasodilator sodium nitroprusside (SNP) 
were obtained under control conditions and following incubation with the ACE-inhibitor 
lisinopril (lisi; 10-5M) alone or in combination with L-NAME (NO-inhibitor), HOE 140 
(bradykinin B2-receptor antagonist) or dichloroisocoumarin (DCI; blocker of kinin-forming 
enzymes). 
Results: In control vessels (n=6), there was maximal vasodilation to His and SNP 
(96±6% and 97±8%, respectively), a diverse effect of 5-HT (19±19%) and predominantly 
vasoconstriction to ACh (-15±21%). Lisi, HOE and DCI did not significantly influence the 
effects of the different agonists. In atherosclerotic vessels (n=6), the vasodilatory effect of 
His was significantly (p<0.05) attenuated (80±2%), 5-HT caused vasoconstriction (- 
20±10%) and constriction to ACh was increased (-27 ±25%), whereas the effect of SNP 
was unaltered (100±3%). Lisi significantly improved the vasodilatory effect of His 
(98±4%) and diminished constriction to 5-HT and ACh (3±11% and -20±18%, respec- 
tively) without altaring the response to SNP (100±1%). Co-treatment with L-NAME, HOE 
or DCI attenuated the effect of lisL 
Conclusions: These results indi~ata that in coronary arterioles from patients with athero- 
sclerosis, treatment with lisinopril acutely increases the effects of endothelial vasodila- 
tors. ACE-inhibitors improve endothelial dysfunction in coronary resistance vessels via 
activation of local kinin production. 
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1081-77 Augmented Gene Transfer in Lungs From Pat ients  With 
Scleroderma 
Hunter C. Champion. John V. Conte, David Kass, Fred Wigley, Johns Hopkins Hospital, 
Baltimore, Maryland. 
The goal of this study was to examine the potential differences in the expression of ade- 
novirus-mediated gene transfer to pulmonary arteries from patients with scleroderma and 
normal donor pulmonary arteries. We used 2 different adenoviral vectors, driven by a 
CMV promoter. Pulmonary arteries were removed from exptanted lungs and cut into 
rings. The artedes were incubated with an adenoviral vector that expresses the reporter 
gene (beta-galactosidase or endothelial nitric oxide synthase (eNOS). Arteries were 
incubated with virus for 2 hours, and then incubated in medium for 24 hours to allow 
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expression of transgene. Transgene expression following exposure to the reporter gene 
was assessed by enzyme activity (Galacto-Light assay) and by a histochemical method 
after X-Gal staining. Transgene expression following transfection with eNOS was 
assessed by histochemical staining and enzyme activity was assessed by the conversion 
of L-arginine to L-citrulline. After gene transfer, I'J-galactosidase or eNOS were expressed 
in endothelium and edventitia but not media. Enzyme activity of eNOS or the reporter 
gene transfer was greater in the pulmonary artery of patients with scleroderma than in 
control arteries. Effects of transgene expression on vascular function were examined by 
recording isometric tension 1 day after transduction. After precontraction with phenyleph- 
dne, ecetylcholine produced significantly less relaxation in vessels from scleroderma 
than in vessels from normal arteries. Relaxation in response to ecetylcholine was greater 
in pulmonary arteries from both normal and scleroderma arteries that were transfected 
with AdeNOS than in vessels treated with vehicle or Adbetagal. Vasorelaxation in 
response to ecetylcholine was inhibited by N-omega-nitro-L-arginine. Responses to 
sodium nitroprusside were similar after treatment with vehicle alone, Adbetagal, or Ade- 
NOS in both groups of arteries. Thus, overaxpression of eNOS with an adenoviral vector 
improves impaired NO-mediated relaxation in human pulmonary arteries and that aden- 
oviral gene-transfer expression is greater in the pulmonary artedes from patients with 
scleroderma than from normal human controls. 
1081-78 Thrombin Generation After  the  Abrupt Cessation of 
Intravenous Unfractionated Heparin Is Mediated by the  
Extrinsic Coagulation Pathway 
Richard C. Becker, YouFu Li, Frederick A. Spencer, University of Massechusetts Medical 
School, Worcester, Massachusetts. 
A "rebound" increase in prothrombotic potential has been observed biochemicaEly and 
clinically after the abrupt cessation of unfrectionated heparin (UFH) among patients with 
acute coronary syndromes. The responsible mechanism(s) have not been determined. 
Methods: In a single-center pilot study, 30 patients with either unstable angina or non-ST 
segment elevation MI who had received a continuous IV infusion of UFH for 48h under- 
went serial blood sampling for markers of thrombin generation (F1.2), intrinsic pathway 
activation (factor Xlla) and extrinsic pathway activation (factor Vlla, tissue factor pathway 
inhibitor [TFPI]) immediately before (baseline) and lh, 4h, and 24h after treatment was 
terminated, The Results are summarized below. Conclusions: Thrombin generation 
increases progressively after UFH cessation and correlates with activation of the extrin- 
sic but not the intrinsic coagulation pathway. Future investigation should focus on the 
effects of pharmacologic thrombin antagonist-mediated prothrombotic potential and the 
specific contribution of impaired tissue factor-directed vascular thromboresistance. 
Coagulation Measurements Over Time (mean values) 
Time Point Heparin F1.2 Factor Xlla Factor Vlla TFPI 
(U/ml) (nM) (ng/ml) (mU/ml) (ng/ml) 
Baseline 0.56 2.22 3.08 38.7 t26.6 
lh 0.34 2.36 3.17 32.2 87.7 
4h 0.12 2.84 3.63 62.6"+ 72,2"*+ 
24h 0.00" 4.40* 2.75 48.4 + 85.3"++ 
*Compared to baseline value, p=O.O01; +correlation with Ft.2 (r=0.85)++; inverse cor- 
relation with F1.2 (r=0.82 and 0.78, respectively) 
1081-79 Long-Term Treatment With Phosphodieaterase Type 5 
Inhibitor Improves Pulmonary Hypertension Caused by 
Congestive Heart Failure Through a Natrluretic 
Peptldes-cGMP Pathway 
Takashi Yamamoto. Atsuyuki Wada, Masato Ohnishi, Takayoshi Tsutamoto, Masanod 
Fujii, Takehiro Matsumoto, Tomoyuki Takayama, Masahiko Kinoshita, Shiga University of 
Medical Science, Otsu, Japan, 
BACKGROUND: Congestive heart failure (CHF) accompanies pulmonary hypertension 
(PH) and PH is an independent predictor of mortality in patients with CHF. Natriuretic 
peptides (NPs) system is activated in CHF and regulates pulmonary vascular tone, how- 
ever, the degradation of cGMP in pulmonary vasculatures is accelerated by phosphodi- 
esterase type 5 (PDE5) in CHF, METHOD: To examine (1) whether long-term treatment 
with a specific PDE5 inhibitor amedolates PH, we administered "1"-1032 (1 mg/kg/day, 
n=7) to dogs with CHF induced by rapid pacing (270 beats/min, 22 days), and CHF con- 
trol dogs were given placebo (n=7); and (2) whether NPs-cGMP pathway is involved in 
the therapeutic effects of "1"-1032 on PH, we injected a specific NPs receptor antagonist, 
HS-142-1 (HS, 3 mg/kg) to clogs after long-term treatment with "1"-1032. RESULTS: In this 
experimentally produced CHF, mean pulmonary pressure (MPAP) and the ratio of right 
ventricular weight/body weight (RV/BW) were significantly increased from 16 to 31 
mmHg, from 1.4 to 2.3, P<0,001, respectively. Plasma atrial natriuretic peptide (ANP) 
and cGMP levels were also higher than the normal dogs (460 vs 46 pg/ml, P<0.001 and 
35 vs 15 pmol/ml, P<0.01, respectively), Long-term treatment of T-1032 further increased 
plasma cGMP level compared with the CHF control dogs (72 vs 35 pmol/ml, p<0.05) 
despite no significant difference in plasma ANP levels (424 vs 460 pg/ml). Without 
adverse hypotensive effect on systemic blood pressure (BP, 94 vs 87 mmHg), T1032 sig- 
nificantly decreased MPAP and RV/BW by 26 % and 18 %, respectively (P<0.05) com- 
pared with those of the CHF control dogs. In the T-1032 group, HS significantly 
suppressed plasma cGMP level from 72 to 40 pmol/ml, p<0.05. MPAP but not BP was 
elevated from 23 to 29 mmHg, p<O.05. In the CHF control group, HS also decreased 
plasma cGMP level from 34 to 10 pmol/ml (p<0.05) but did not affect MPAP. CONCLU- 
SION: Long-term treatment with T-1032 exerts an important role in the regulation of PH 
through the NPs-cGMP pathway without hypotensive effect in CHF. PDE5 inhibitor may 
be an attractive therapeutic agent for CHF-induced PH. 
1081-80 Ef fects  of  the  Oral Endothe l in  Receptor Antagonist 
Bosentan on Echocardlographic and Doppler Measures 
in Patients With Pulmonary Arterial Hypertension 
~ ,  Alan L. Hioderiiter, Adam Torbicki, Gerald Simonneau, Nilda Espinola- 
Zabaleta, Guido Rocchi, Marcin Kurzyna, Andrew Kronenperg, Robert Frantz, Nagueh 
Sherif, Robyn Barst, Karl Dujardin, Richard Channick, for the BREATHE-1 Echo 
Substudy Group, Institute of Cardiology, University of Bologna, Bologna, Italy. 
Background: Bosentan, an orally active dual endothelin receptor antagonist, improves 
symptoms, exercise capacity, and hemodynamics in patients with pulmonary artedal 
hypertension. In the present study, the effects of bosentan (125 or 250 mg bid) on 
echocardiographic and Doppler variables were analysed in a subgroup of 85 patients 
with WHO class Iti and IV pulmonary arterial hypertension enrolled in the prospective, 
double blind, placebo-controlled BREATHE-1 study. 
Methods: The majority of patients (84%) had primary pulmonary hypertension. 29 
patients received placebo and 56 received bosentan in a 1:2 randomization procedure. 
6-minute walk tests and echocardiograms were performed at baseline and after 16 
weeks. Echocardiograms were recorded in 13 centers and measurements were per- 
formed in a core laboratory. 
Results: Baseline clinical, hemodynamic and echocardiegraphic characteristics were 
similar in the placebo and bosentan groups. On baseline evaluation, echocardiographic 
and Doppler variables were consistent with marked abnormalities of nght (RV) and left 
(LV) ventricular structure and function. The treatment effect (difference between treat- 
ment groups in the mean change at week 16) on 6-minute walking distance was 37 m in 
favor of bosentan (p = 0.036). Time velocity integrals of the LV outflow tract and of mitral 
inflow were improved in the bosentan group and resulted in a treatment effect on Dop- 
pler-derived cardiac index of + 0.4 I/min/m 2 (p = 0.007). Treatment effects of bosentan on 
other echocardiograPhic and Doppler parameters were as follows: E/A ratio = + 0.18 (p = 
0.004), LV end-diastolic area = + 4.2 cm 2 (p = 0.003), LV systolic eccentricity index = - 
0.12 (p = 0.047), RV end-systolic area = - 2.3 cm 2 (p = 0.057), LV/RV diastolic areas ratio 
= + 0,16 (p= 0.04), RV diastolic remodeling index (minor/major axis ratio) = - 0.06 (p = 
0.004), RV ejection time = + 22 msec (p = 0,007), Doppler RV (Tei) index = - 0.06 (p = 
0.03), inferior vena cava minimum diameter = - 0.22 cm (p = 0.03), pericardial effusion 
score = - 0.54 (p = 0.05). 
Conclusions: Bosentan improves RV systolic function and LV early diastolic filling and 
leads to reverse ventricular remodeling in patients with pulmonary arterial hypertension. 
1081-81 Oral S i ldenaf i l  Is an Ef fect ive and Speci f ic  Pulmonary 
Vasodilator in Patients With Pulmonary Arterial 
Hypertension 
Evangelos D. Michelakis, Wavne Tvmchak, Dale Lien, Linda DaSilva, Kyoko Hashimoto, 
Stephen L. Archer, University of Alberta, Edmonton, Alberta, Canada. 
Background: The prognosis of patients with severe pulmonary hypertension (PHT) is 
poor. To determine prognosis and guide chronic therapy, an acute trial of a selective pul- 
monary vasodilator, usually inhaled nitric oxide (iNO), is performed during cardiac cathe- 
terization. We hypothesized that oral sildenafil, a phosphodiesterase V inhibitor, is a safe 
and effective alternative to iND. 
Methods: We studied 12 consecutive patients (mean±SEM, 43±2 years, 8 female) 
referred during one year, for consideration of heart-lung transplantation or as a guide to 
medical therapy. All but one were functional class IV. Subjects had primary PHT (8), pul- 
monary arterial hypertension (2) or secondary PHT (2). Hemodynamics and serum cyclic 
guanosine monophosphate levels (c-GMP) were measured at baseline and at peak 
effects of iNO (80 ppm), sildenafil (75 mg) or their combination. 
Results: The decrease in pulmonary vascular resistance was similar with iNO (-20±6%) 
and sildenafil (-25±3%) while sildenafil+iNO was more effective than iNO alone (-32±5%, 
p<0.03). Sildenafil and sildenafil+iNO increased cardiac output (15±6 and 15±4%, 
respectively) whereas iNO did not (0,3±3.0%, p<0.003), iNO increased, whereas sildena- 
fil tended to decrease pulmonary-capillary wedge pressure (+17±7 versus -9±8%, p< 
0.001 ). Systemic arterial pressure was similar amongst groups and did not decrease with 
treatment, cGMP levels increased similarly with iNO and sildenafil and their combination 
elevated cGMP more (p<0.05). 
Conclusions: A single oral dose of sildenafil is as effective and selective a pulmonary 
vasodilator as iNO. Sildenafil may be superior to iNO in that it causes greater increase in 
cardiac output and does not increase wedge pressure. Future studies are indicated to 
establish whether sildenafil could also be effective chronically. 
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1082-72 Carbon Monoxide Decreases Pulmonary Vascular 
Resistance and Blocks Hypoxic Pulmonary 
Vasoconstriction in the Rat 
Albert L. Hymen. Syed R. Baber, Robert L Johnson, Philip J. Kadowitz, Tulane 
University Medical Center, New Orleans, Louisiana. 
The effects of carbon monoxide (CO) and the heme oxygenase inhibitor chromium mesopo- 
rphydn (CM) ~n the pulmonary circulation was investigated in the intact-chest rat. Pulmo- 
nary arterial (PA) and wedge pressures were measured using a newly developed right-heart 
